Evidence map›Paper›PMID 33772615›Full record

ArticleAbdominal radiology (New York)2021

Impact of 18F-FDG PET/MR based tumor delineation in radiotherapy planning for cholangiocarcinoma.

Gauthier Delaby, Bahar Ataeinia, Jennifer Wo, Onofrio Antonio Catalano, Pedram Heidari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Abdominal radiology (New York), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Radiotherapy volume delineation based on MRI andAbdominal radiology (New York) · 2025
    Article
  2. Application ofDiagnostics (Basel, Switzerland) · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gauthier Delaby *Department of Nuclear Medicine, University of Lille, Lille, France.
Bahar Ataeinia *Department of Radiology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jennifer WoDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Onofrio Antonio CatalanoDepartment of Radiology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ocatalano@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-7733-4138
Pedram HeidariDepartment of Radiology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Funding

Enhancing the therapeutic effect of receptor radionuclide therapy in neuroendocrine tumors by somatostatin receptor upregulationK08CA249047 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HEIDARI, PEDRAM · 2020 to 2024
$1.3M
NCI NIH HHS K08 CA249047
6 · The paper itself

Abstract

purposeRadiation therapy (RT) is an effective treatment for unresectable cholangiocarcinoma (CC). Accurate tumor volume delineation is critical in achieving high rates of local control while minimizing treatment-related toxicity. This study compares

methodsWe retrospectively included 22 patients with newly diagnosed unresectable primary CC who underwent

resultsGTV

conclusion

Indexed as

CholangiocarcinomaFluorodeoxyglucose F18HumansPositron-Emission TomographyRadiopharmaceuticalsRetrospective StudiesTumor BurdenFluorodeoxyglucose F18RadiopharmaceuticalsCholangiocarcinomaGross tumor volumePET/MRRadiation therapy

Identifiers

PMID33772615
PMCPMC8289745

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.